NCT00757250View on ClinicalTrials.gov

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
HIV Infections
Interventions
DRUG

Angiotensin 1-7

Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Trial Locations (3)

90033

LAC+USC Medical Center, Rand Schrader Clini, Los Angeles

90502

Harbor - UCLA Medical Center, Torrance

92103

UCSD Division of Infectious Diseases, San Diego

Sponsors

Collaborators (1)

Tarix Pharmaceuticals
All Listed Sponsors
collaborator

Tarix Pharmaceuticals

INDUSTRY

lead

US Biotest, Inc.

INDUSTRY

NCT00757250 - Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy | Biotech Hunter | Biotech Hunter